Revestive
Shire gets extended market authorization in Europe for drug to treat children with a rare gastrointestinal condition
July 7, 2016Research and Development, Sales and Marketing European Commission, Revestive, Shire, market authorisation, short bowel syndrome
UK drugmaker Shire (LSE: SHP) said the European Commission has granted extension of Market Authorization for Revestive (teduglutide) to treat …
Shire gets positive opinion from EMA on rare gastrointestinal disease treatment
May 27, 2016Medical Communications, Research and Development, Sales and Marketing CHMP, EMA, Revestive, Shire, gastrointestinal, paediatric, short bowel syndrome, treatment
Shire (LSE: SHP) has announced that it has received a positive opinion from the European Medicines Agency’s (EMA) Committee for …
Nycomed files short bowel syndrome treatment
March 28, 2011Medical Communications Nycomed, Revestive, gastrointestinal
Specialist pharma company Nycomed has submitted a novel bowel disease treatment for assessment by European regulators. The Marketing Authorisation Application …
Latest content
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
October 13, 2026
Tridem begins phase Ib trial of Parkinson’s disease vaccine
October 13, 2026
Trio become latest Symbiosis commercial additions
October 12, 2026
UK immunoglobulin supply faces growing pressure, report warns
October 12, 2026
